QingSong Health Group and Tencent Health jointly build BioMed AI, Zheng Yuanfang expands industrial application scenarios

On October 29, 2026, the 2026 Tencent Global Digital Ecosystem Summit opened in Shenzhen. During the summit, Qingsong Health Group (02661.HK) was honored with the "2026 Tencent Cloud Network Services Industry Ecosystem Partner Award," and appeared as an important ecosystem partner in the healthcare sector at the Smart Healthcare special session, joining industry leaders such as WeDoctor and Meinian Onehealth to jointly advance the building of BioMed AI. This collaboration further deepened the industrial synergy between Qingsong Health Group and Tencent Health, providing new ecosystem support for the Group's self-developed evidence-based medicine agent "Zheng Yuanfang" to expand professional application scenarios and advance large-scale adoption.

Previously, Tencent announced its open ecosystem strategy at the WorkBuddy ecosystem launch event and introduced the "Buddy App" platform. Based on the WorkBuddy general-purpose foundation, Tencent Health partnered with leading industry enterprises to build the one-stop AI workbench BioMed AI. As the first official industry application of WorkBuddy, the platform covers four core scenarios—scientific research and pharmaceuticals, clinical assistance, patient management, and marketing and compliance—connecting expert Agents, professional Skills, and business systems through a unified task entry point, driving medical AI to evolve from point tools toward cross-scenario, cross-process collaborative applications.

Within this ecosystem, Tencent provides the general-purpose technology foundation and platform connectivity capabilities, while industry partners such as Qingsong Health Group leverage their strengths in professional technology, product capabilities, and accumulated healthcare scenario experience to jointly advance the industrialization of medical AI solutions.

For Qingsong Health Group, participating in the co-building of the BioMed AI ecosystem helps expand the application reach of its self-developed AI products, further connect with medical institutions, research, and pharmaceutical industry clients, and explore standardized, replicable AI service models. The complementarity between the two parties in technical capabilities, industry resources, and application scenarios also creates conditions for medical AI to move from product innovation toward large-scale services.

As an important product of Qingsong Health Group's AI + healthcare strategy, the evidence-based medicine agent "Zheng Yuanfang" relies on the Group's self-developed AIcare technology stack and addresses the needs of medical professionals in evidence retrieval, literature interpretation, and clinical research protocol design. Through multi-agent collaboration, it integrates capabilities such as task decomposition, evidence retrieval, guideline comparison, and process archiving, providing explainable, verifiable, and traceable professional support.

According to the Group's 2026 interim report, as of June 30, 2026, Zheng Yuanfang had more than 100,000 registered users, including more than 80,000 certified medical professional users. This continuously growing base of professional users supports product iteration, scenario adaptation, and expansion of institution-level services, and also lays the foundation for the Group's exploration of large-scale delivery of medical AI.

From the perspective of industrial value, the commercialization of medical AI depends not only on technical capabilities but also on professional scenario coverage, customer reach efficiency, and continuous delivery capability. By accumulating professional AI capabilities through independent research and development and leveraging the platform resources and industrial connectivity advantages of the Tencent Health ecosystem, Qingsong Health Group is expected to further expand the service boundaries of its medical AI products and enhance the scenario adaptability and large-scale application capabilities of its solutions.

In the future, Qingsong Health Group will continue to deepen ecosystem cooperation with Tencent Health and industry partners, promote the deep integration of evidence-based medicine AI capabilities with healthcare business scenarios, explore sustainable service models for medical institutions and industry clients, accelerate the transformation of technological advantages into industrial application value, and cultivate new business growth drivers for the Group.